Floatz logo

Epirubicin

B-Cell Acute Lymphoblastic Leukemia, Adult

University of California, San DiegoPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the B-Cell Acute Lymphoblastic Leukemia, Adult cohort.

Asset / SponsorPhaseRating
cd19-ucart
The General Hospital of Western Theater Command
Phase 2BBB
Blinatumomab
Memorial Sloan Kettering Cancer Center
Phase 2BB
cd22 car-transduced t cells
Zhejiang University
Phase 2BB
Fludarabine
The First Affiliated Hospital of Soochow University
Phase 1/2B
Venetoclax
Zhejiang University
Phase 2CCC

View all 9 →

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →